{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T01:22:32Z","timestamp":1788744152206,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40262-025-01566-5","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:02:13Z","timestamp":1762959733000},"page":"149-164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Population Pharmacokinetics of Atogepant for the Prevention of Migraine"],"prefix":"10.1007","volume":"65","clinical-trial-number":[{"clinical-trial-number":"nct03855137","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5822-4246","authenticated-orcid":false,"given":"Louisa","family":"Schlachter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7986-4447","authenticated-orcid":false,"given":"Sven","family":"Stodtmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Voelkner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5118-4247","authenticated-orcid":false,"given":"Hendrik Maxime","family":"Lagraauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8267-9210","authenticated-orcid":false,"given":"Ramesh R.","family":"Boinpally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"5","key":"1566_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/14737175.2024.2332754","volume":"24","author":"S Alabbad","year":"2024","unstructured":"Alabbad S, Figueredo N, Yuan H, Silberstein S. Developments in targeting calcitonin gene-related peptide. Expert Rev Neurother. 2024;24(5):477\u201385. https:\/\/doi.org\/10.1080\/14737175.2024.2332754.","journal-title":"Expert Rev Neurother"},{"issue":"11","key":"1566_CR2","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1080\/17512433.2024.2417655","volume":"17","author":"M Waliszewska-Prosol","year":"2024","unstructured":"Waliszewska-Prosol M, Raffaelli B, Straburzynski M, Martelletti P. Understanding the efficacy and tolerability of migraine treatment: a deep dive into CGRP antagonists. Expert Rev Clin Pharmacol. 2024;17(11):1039\u201351. https:\/\/doi.org\/10.1080\/17512433.2024.2417655.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"1566_CR3","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1007\/s00415-023-11706-1","volume":"270","author":"F Puledda","year":"2023","unstructured":"Puledda F, Silva EM, Suwanlaong K, Goadsby PJ. Migraine: from pathophysiology to treatment. J Neurol. 2023;270(7):3654\u201366. https:\/\/doi.org\/10.1007\/s00415-023-11706-1.","journal-title":"J Neurol"},{"issue":"8","key":"1566_CR4","doi-asserted-by":"publisher","first-page":"333102423119029","DOI":"10.1177\/03331024231190296","volume":"51","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Halker Singh RB, Mechtler L, McVige J, Ma J, Yu SY, et al. Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial. Cephalalgia. 2023;51(8):3331024231190296. https:\/\/doi.org\/10.1177\/03331024231190296.","journal-title":"Cephalalgia"},{"issue":"Suppl 2","key":"1566_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/head.13081","volume":"57","author":"L Edvinsson","year":"2017","unstructured":"Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(Suppl 2):47\u201355. https:\/\/doi.org\/10.1111\/head.13081.","journal-title":"Headache"},{"issue":"1","key":"1566_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","volume":"22","author":"LH Lassen","year":"2002","unstructured":"Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002;22(1):54\u201361. https:\/\/doi.org\/10.1046\/j.1468-2982.2002.00310.x.","journal-title":"Cephalalgia"},{"issue":"1","key":"1566_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33(1):48\u201356. https:\/\/doi.org\/10.1002\/ana.410330109.","journal-title":"Ann Neurol"},{"issue":"10","key":"1566_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s11916-023-01167-6","volume":"27","author":"S Cho","year":"2023","unstructured":"Cho S, Kim B-K. Update of gepants in the treatment of chronic migraine. Curr Pain Headache Rep. 2023;27(10):561\u20139. https:\/\/doi.org\/10.1007\/s11916-023-01167-6.","journal-title":"Curr Pain Headache Rep"},{"issue":"5","key":"1566_CR9","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/head.13791","volume":"60","author":"D Tepper","year":"2020","unstructured":"Tepper D. Gepants. Headache. 2020;60(5):1037\u20139. https:\/\/doi.org\/10.1111\/head.13791.","journal-title":"Headache"},{"issue":"8","key":"1566_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11940-017-0463-4","volume":"19","author":"AR Tso","year":"2017","unstructured":"Tso AR, Goadsby PJ. Anti-CGRP monoclonal antibodies: the next era of migraine prevention? Curr Treat Options Neurol. 2017;19(8):27. https:\/\/doi.org\/10.1007\/s11940-017-0463-4.","journal-title":"Curr Treat Options Neurol"},{"issue":"2","key":"1566_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/bcp.12618","volume":"80","author":"L Edvinsson","year":"2015","unstructured":"Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. 2015;80(2):193\u20139. https:\/\/doi.org\/10.1111\/bcp.12618.","journal-title":"Br J Clin Pharmacol"},{"key":"1566_CR12","volume-title":"Triptans","author":"S Nicolas","year":"2025","unstructured":"Nicolas S, Nicolas D. Triptans. Treasure Island: StatPearls; 2025."},{"issue":"1","key":"1566_CR13","first-page":"17","volume":"99","author":"H Ha","year":"2019","unstructured":"Ha H, Gonzalez A. Migraine headache prophylaxis. Am Fam Physician. 2019;99(1):17\u201324.","journal-title":"Am Fam Physician"},{"key":"1566_CR14","unstructured":"Coordination Group for Mutual Recognition and Decentralised Procedures (CMDh). European Medicines Agency Website. Topiramate article 31\u2014new measures to avoid topiramate exposure in pregnancy. October 13, 2023. Accessed Apr 22, 2025. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/topiramate-article-31-referral-new-measures-avoid-topiramate-exposure-pregnancy_en.pdf."},{"issue":"1","key":"1566_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13707","volume":"17","author":"R Boinpally","year":"2024","unstructured":"Boinpally R, Shebley M, Trugman JM. Atogepant: mechanism of action, clinical and translational science. Clin Transl Sci. 2024;17(1):e13707. https:\/\/doi.org\/10.1111\/cts.13707.","journal-title":"Clin Transl Sci"},{"issue":"11","key":"1566_CR16","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa030505","volume":"350","author":"J Olesen","year":"2004","unstructured":"Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350(11):1104\u201310. https:\/\/doi.org\/10.1056\/NEJMoa030505.","journal-title":"N Engl J Med"},{"key":"1566_CR17","unstructured":"QULIPTA (atogepant). North Chicago, IL, USA. AbbVie Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215206s004lbl.pdf. Revised June 2023. Accessed Feb 5, 2025."},{"key":"1566_CR18","doi-asserted-by":"publisher","DOI":"10.2217\/pmt-2023-0056","author":"R Boinpally","year":"2023","unstructured":"Boinpally R, Chen W, McGeeney D, Trugman JM. Effects of CYP3A4 inhibition\/induction and OATP inhibition on the pharmacokinetics of atogepant in healthy adults. Pain Manag. 2023. https:\/\/doi.org\/10.2217\/pmt-2023-0056.","journal-title":"Pain Manag"},{"issue":"8","key":"1566_CR19","doi-asserted-by":"publisher","first-page":"e764","DOI":"10.1212\/WNL.0000000000201568","volume":"100","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes JT, et al. Effect of atogepant for preventive migraine treatment on patient-reported outcomes in the randomized, double-blind, phase 3 ADVANCE trial. Neurology. 2023;100(8):e764\u201377. https:\/\/doi.org\/10.1212\/WNL.0000000000201568.","journal-title":"Neurology"},{"key":"1566_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01049-8","author":"P Pozo-Rosich","year":"2023","unstructured":"Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023. https:\/\/doi.org\/10.1016\/S0140-6736(23)01049-8.","journal-title":"Lancet"},{"issue":"4","key":"1566_CR21","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(24)00025-5","volume":"23","author":"C Tassorelli","year":"2024","unstructured":"Tassorelli C, Nagy K, Pozo-Rosich P, Lanteri-Minet M, Sacco S, Nezadal T, et al. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. Lancet Neurol. 2024;23(4):382\u201392. https:\/\/doi.org\/10.1016\/S1474-4422(24)00025-5.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1566_CR22","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/head.14433","volume":"63","author":"AM Blumenfeld","year":"2023","unstructured":"Blumenfeld AM, Boinpally R, De Abreu Ferreira R, Trugman JM, Dabruzzo B, Ailani J, et al. Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine. Headache. 2023;63(3):322\u201332. https:\/\/doi.org\/10.1111\/head.14433.","journal-title":"Headache"},{"issue":"3","key":"1566_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit\u2013a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241\u201357. https:\/\/doi.org\/10.1016\/j.cmpb.2005.04.005.","journal-title":"Comput Methods Programs Biomed"},{"issue":"2","key":"1566_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351. https:\/\/doi.org\/10.1208\/s12248-011-9255-z.","journal-title":"AAPS J"},{"key":"1566_CR25","unstructured":"Bergstrand M. Application relevant shrinkage metrics. Abstract\/poster (Abstr 10663) presented at: Population Approach Group Europe (PAGE 31); June 28-30, 2023; Plalexco A Coruna, Spain. www.page-meeting.org\/?abstract=10663."},{"issue":"6","key":"1566_CR26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40261-021-01034-5","volume":"41","author":"R Boinpally","year":"2021","unstructured":"Boinpally R, Spaventa J, Chen K, Butler M. Evaluation of the pharmacokinetic interaction and safety of atogepant co-administered with acetaminophen or naproxen in healthy participants: a randomized trial. Clin Drug Investig. 2021;41(6):557\u201367. https:\/\/doi.org\/10.1007\/s40261-021-01034-5.","journal-title":"Clin Drug Investig"},{"issue":"8","key":"1566_CR27","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1002\/cpdd.1407","volume":"13","author":"R Boinpally","year":"2024","unstructured":"Boinpally R, Borbridge L, Wangsadipura V. Pharmacokinetics and safety of atogepant co-administered with quinidine gluconate in healthy participants: a phase 1, open-label, drug-drug interaction study. Clin Pharmacol Drug Dev. 2024;13(8):930\u20137. https:\/\/doi.org\/10.1002\/cpdd.1407.","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01566-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01566-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01566-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T15:31:01Z","timestamp":1767886261000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01566-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1566"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01566-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AbbVie funded these studies and participated in the trial design, research, analysis, data collection and interpretation, and the publication\u2019s review and approval. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Louisa Schlachter, Sven Stodtmann, and Ramesh R. Boinpally are AbbVie employees and may hold AbbVie stock or options. Alexander Voelkner, Fredrik Jonsson, and Hendrik Maxime Lagraauw are employees of qPharmetra LLC.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g., protocols, clinical study reports, or analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent, scientific research, and will be provided following review and approval of a research proposal, statistical analysis plan (SAP), and execution of a data sharing agreement (DSA). Data requests can be submitted at any time after approval in the USA and Europe and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered. For more information on the process or to submit a request, visit the following link:\n                      \n                      , then select \u201cHome.\u201d","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Sharing"}},{"value":"The studies reported herein were conducted in accordance with the International Council for Harmonisation (ICH) guidelines, applicable regulations, and guidelines governing clinical study conduct and the ethical principles that have their origin in the Declaration of Helsinki. Approval was granted by institutional review boards and independent ethics committees at participating institutions.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided written consent prior to participation or study-related procedures.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All individual participants signed informed consent regarding publishing their data.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization: L.S., S.S., and R.R.B. Data curation, formal analysis, methodology, and visualization: all authors. Writing\u2014original draft: L.S. All authors critically reviewed and edited drafts of this manuscript and approved the final draft for publication.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}